INFLAMMATION and VASCULAR FUNCTION in ACUTE STROKE and TIA: TREATMENT WITH ATORVASTATIN and IRBESARTAN

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000175673

Acronym

VCAPS-T

Enrollment

Registered

2005-08-19

Start date

2005-05-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Atorvastatin 80mg or Irbesartan 150mg for 21 days

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Patients presenting to facilities of the North Metropolitan Area Health Service within 10 days of acute ischaemic stroke.

Exclusion criteria

Finger prick or laboratory blood sugar level > 13 mmol/L at baseline; - Acute co morbid condition (such as myocardial ischaemia or sepsis); - Pre-menopausal female; - Haemorrhage seen on initial CT.Statin exclusion criteria: - History of sensitivity to statins; - Active liver disease or unexplained elevation in transaminasesIrbesartan exclusion criteria: - Hypotension (SBP< 100mmHg or DBP<70mmHg); - Hypertension (>220 mmHg) or clinical imperative to lower blood pressure hyperkalaemia: >5.5 mmol/L; - History of sensitivity to ATRA; - Renal impairment (defined as creatinine >120 umol/L); - Current treatment with an ATRA or more than one of an ACE inhibitor, non steroidal anti-inflammatory, potassium sparing diuretic, potassium salt or cyclosporin.

Outcome results